Most Read Articles
5 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
4 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
2 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 4 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

Obesity, sarcopenic obesity increase risk of knee osteoarthritis

11 Oct 2018

Obese and sarcopenic obese individuals are at high risk of knee osteoarthritis (OA), a study has found.

The study cohort comprised 1,667 individuals (mean age 62 years; 58 percent female; mean body mass index [BMI], 30 kg/m2) without radiographic knee OA at baseline participating in the Multicenter Osteoarthritis (MOST) study. A total of 1,653 who completed the 60-month follow-up were included in the final analysis.

Body composition (ie, fat and muscle mass) was measured using whole body dual energy x‐ray absorptiometry and categorized as obese, sarcopenic obese, sarcopenic and nonsarcopenic nonobese. These categories were then examined in relation to the risk of incident radiographic OA at 5 years using binomial regression adjusting for potential confounders.

There were 315 participants (19 percent) who developed radiographic knee OA over the study period. The risk of incident radiographic knee OA was significantly elevated in the obese group (women: risk ratio [RR], 2.29; 95 percent CI, 1.64–3.20; men: RR, 1.73; 1.08–2.78) and in the sarcopenic obese group only among women (RR, 1.91; 1.17–3.11) but not among men (RR, 1.74; 0.68–4.46).

On the other hand, the risk increase was not seen in the sarcopenia group (women: RR, 0.96; 0.62–1.49; men: RR, 0.66; 0.34–1.30).

The present data have implications for the management and prevention of knee OA, such that weight loss interventions should target both high fat and low muscle mass, researchers said.

The study was limited by the small sample size of sarcopenic obesity, the inclusion of Caucasians primarily and the observational nature of the study, among others.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
4 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
2 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 4 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.